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Abstract
Background: The assessment of post-myocardial infarction (MI) left ventricular (LV) remodeling by cardiovascular
magnetic resonance (CMR) currently uses criteria defined by echocardiography. Our aim was to provide CMR
criteria for assessing LV remodeling following acute MI.
Methods: Firstly, 40 reperfused ST-segment elevation myocardial infarction (STEMI) patients with paired acute
(4 ± 2 days) and follow-up (5 ± 2 months) CMR scans were analyzed by 2 independent reviewers and the minimal
detectable changes (MDCs) for percentage change in LV end-diastolic volume (%ΔLVEDV), LV end-systolic volume
(%ΔLVESV), and LV ejection fraction (%ΔLVEF) between the acute and follow-up scans were determined. Secondly,
in 146 reperfused STEMI patients, receiver operator characteristic curve analyses for predicting LVEF <50% at
follow-up (as a surrogate for clinical poor clinical outcome) were undertaken to obtain cut-off values for %ΔLVEDV
and %ΔLVESV.
Results: The MDCs for %ΔLVEDV, %ΔLVESV, and %ΔLVEF were similar at 12%, 12%, 13%, respectively. The cut-off
values for predicting LVEF < 50% at follow-up were 11% for %ΔLVEDV on receiver operating characteristic curve
analysis (area under the curve (AUC) 0.75, 95% CI 0.6 to 0.83, sensitivity 72% specificity 70%), and 5% for %ΔLVESV (AUC
0.83, 95% CI 0.77 to 0.90, sensitivity and specificity 78%). Using cut-off MDC values (higher than the clinically important
cut-off values) of 12% for both %ΔLVEDV and %ΔLVESV, 4 main patterns of LV remodeling were identified in our
cohort: reverse LV remodeling (LVEF predominantly improved); no LV remodeling (LVEF predominantly unchanged);
adverse LV remodeling with compensation (LVEF predominantly improved); and adverse LV remodeling (LVEF
unchanged or worsened).
Conclusions: The MDCs for %ΔLVEDV and %ΔLVESV between the acute and follow-up CMR scans of 12% each
may be used to define adverse or reverse LV remodeling post-STEMI. The MDC for %ΔLVEF of 13%, relative to baseline,
provides the minimal effect size required for investigating treatments aimed at improving LVEF following acute STEMI.
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Background
Despite prompt reperfusion of acute ST-elevation myo-
cardial infarction (STEMI) by primary percutaneous
coronary intervention (PPCI), adverse left ventricular
(LV) remodeling still occurs in a significant proportion
of patients [1], and its presence predisposes to heart
failure [2] and worse clinical outcomes [3]. In contrast,
some reperfused STEMI patients develop reverse LV re-
modeling, which portends to good clinical outcomes [4].
Cardiovascular magnetic resonance (CMR) is considered
the gold-standard imaging modality for quantifying myo-
cardial infarct (MI) size [5], and measuring LV volumes
and LV ejection fraction (LVEF) [5, 6], given its high
reproducibility [5, 7]. As a result, CMR is increasingly
being used to assess surrogate clinical end-points fol-
lowing STEMI in cardioprotection studies. Adverse LV
remodeling following STEMI has been conventionally
defined as ≥ 20% increase in LV end-diastolic volume
(LVEDV) from baseline. This cut-off value was deter-
mined using echocardiography, and was based on the
upper limit of the 95% confidence interval of intra-
observer variability for the percentage change (%Δ) in
LVEDV following STEMI [8, 9]. Reverse LV remodeling
has been defined as ≥10% decrease in LV end-systolic
volume (LVESV) by echocardiography following cardiac
resynchronization therapy, and was derived using re-
ceiver operator characteristic (ROC) curves for the op-
timal cut-off for the %ΔLVESV to predict mortality
[10]. So far, no cut-off values for adverse and reverse
LV remodeling following STEMI have been defined by
CMR, and studies using CMR to assess post-STEMI LV
remodeling have relied upon using these cut-off values
defined by echocardiography for adverse [11, 12] and
reverse LV remodeling [13].
Therefore, the first aim of this study was to perform
intra-observer and inter-observer measurements of LV pa-
rameters in paired acute and follow-up CMR scans in re-
perfused STEMI patients, in order to determine the
minimal detectable changes (MDCs) that could be used as
cut-off values for defining post-STEMI remodeling. Sec-
ondly, we aimed to identify the cut-off values for clinically
important %ΔLVEDV and %ΔLVESV to predict LVEF
<50% at follow-up [14], as a surrogate for poor clinical
outcome [15]. Finally, cut-off values for %ΔLVEDV and
%ΔLVESV were then applied to a large cohort of STEMI
patients with paired acute and follow-up scans to assess
different patterns of post-STEMI LV remodeling.
Methods
Patients included in this study have been reported previ-
ously in 4 separate studies [16–19] as summarized in the
Additional file 1: Online appendix Table 1. All patients
provided informed consent at the time of recruitment and
the studies were conducted according to the Declaration
of Helsinki. Only patients with a paired acute CMR within
the first week post PPCI and a follow-up CMR were
included in this study.
Cohort for inter-observer and intra-observer analysis
Analysis was performed using CVI42 software (Version
5.2.2, Calgary, Canada). Forty STEMI patients reper-
fused by PPCI, with paired acute and follow-up scans
from one of the cohorts reported recently [19–21] were
used for inter and intra-observer variability. Semi-
automated contours were drawn on the short-axis cine
images using the threshold segmentation option for the
epicardial border and the automatic detection option
for the endocardial border, with manual adjustment
when required. The LVEDV, LVESV, LV mass (LVM)
and LVEF were quantified using 2 methods as shown in
Fig. 1. In method 1, we used rounded endocardial con-
tours and excluded the trabeculae and papillary muscles
(T&P) as part of the LVM and they were included as
part of the LV volume. In method 2, the T&P were in-
cluded as part of the LVM and they were excluded from
the LV volume. The basal cine slice was included if at
least 50% of the cavity circumference was surrounded
by ventricular myocardium and this principle was used
for both end-systole and end-diastole. %ΔLVEDV,
%ΔLVESV, %ΔLVM and %ΔLVEF were calculated as the
difference between the follow-up parameters and the
corresponding baseline parameters and expressed as a
percentage of the baseline parameters. All 40 acute and
matching follow-up scans were analysed by 2 experi-
enced CMR operators (twice by HB, 3 years’ experience
in CMR, at least 2 months apart and blinded to previ-
ous results, and once by YYG, 1 and a half years’
experience in CMR).
Cohort for LV remodeling
Patient level data were obtained from our 2 previously
reported cohorts [18, 19], and from 2 previous random-
ized controlled trials [16, 17] as listed in the Additional
file 1: Online appendix Table 1. Only patients with
paired acute and follow-up CMR scans were included.
The LV parameters reported by the original studies were
used for analysis. All cines were acquired using steady-
state free precession-based cines as previously described
in their respective publications [16–19]. The CMR de-
tails for the acute MI size and microvascular obstruction
(MVO) assessment by the 4 different cohorts of patients
included are summarized in the Additional file 1: Online
appendix Table 1.
Statistical analysis
Statistical analysis was performed using SPSS version 22
(IBM Corporation, Illinois, US). Normality was assessed
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using Shapiro-Wilk Test. Continuous data was expressed
as mean ± standard deviation (SD) or median (interquar-
tile range) and categorical data was reported as frequen-
cies and percentages. Groups were compared using
paired Student t test/Wilcoxon signed rank test or
unpaired Student t test/Mann Whitney U test where
appropriate. One-way analysis of variance was used to
obtain the mean squared error for each LV parameter
for inter and intra-observer measurements and their cor-
responding square root provided their standard error of
the measurement (SEM). The 95% confidence interval
(CI) for each SEM was calculated as previously described
[22]. Coefficient of variation (CoV) was expressed as the
standard deviation of the difference divided by the mean
and expressed as a percentage and Levene’s test for
homogeneity of variance was used to compare CoV
between the two methods used for LV parameters quan-
tification (T&P being part of the LV mass or LV volume).
Bland-Altman analysis was performed for inter and
intra-observer measurements of the LV parameters for
comparison. The MDCs with 95% confidence (MDC95)
for intra and inter-observer measurements for
%ΔLVEDV, %ΔLVESV, % LVM and %ΔLVEF was calcu-
lated as 1.96 x SEM x square root of 2. ROC curve ana-
lysis was performed to predict an LVEF of <50% at
follow-up to identify clinically significant cut-off values
for %ΔLVEDV and %ΔLVESV. All statistical tests were
two-tailed, and P < 0.05 was considered statistically
significant.
Results
The mean age of the 40 STEMI patients used for intra-
observer and inter-observer measurements was 59 ±
13 years old and 35 (88%) were male. Details of the
paired acute and follow-up CMR scans are shown in
Table 1. The acute CMR scan was performed at 4 ±
2 days post-PPCI and the follow-up CMR scan was
performed at 5 ± 2 months.
Variability of LV parameters between the acute and
follow-up CMR scans
Table 2 summarizes the SEM (95%CI), CoV and Bland-
Altman analysis of the LV parameters divided into acute
and follow-up scans and quantification method. Compari-
son of CoV did not show any statistical difference for
inter-observer or intra-observer measurements (LVEDV,
LVESV, LVM, LVEF) on both the acute or follow-up scans
between both LV quantification methods (T&P included
as part of the LV volume or LV mass) (P values
between 0.15 and 0.97).
The LVEDV and LVESV were significantly higher and
the LVM and LVEF were significantly lower both on
the acute and follow-up scans when the T&P were in-
cluded as part of the LV volume as shown in Fig. 2.
When they were included as part of the LVM, they con-
tributed the same extent to the LV mass on the acute
and the follow-up scans (12.9 ± 5.1 and 11.4 ± 6.3%
respectively, P = 0.17).
Variability of %Δ in LV parameters
Details on the intra-observer and inter-observer measure-
ments for %ΔLVEDV, %ΔLVESV, %ΔLVM and %ΔLVEF,
both for when T&P was included as part of either LV
volume or LV mass, are provided in Table 3. The MDC95
values for these LV parameters were similar for inter- and
End-diastole End-systole 
Method 1:  
trabeculae 
and papillary muscles  
included as part of LV 
volume 
Method 2:  
trabeculae 
and papillary muscles  
included as part of LV 
mass  
Fig. 1 Quantification of LV parameters with T&P part of LV volume (method 1) and part of LV mass (method 2)
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intra-observer measurements, and whether the T&P were
included as part of the LV volume or mass.
Irrespective of how the T&P were dealt with, the highest
MDC95 was 11% for %ΔLVEDV and 10% for %ΔLVESV
for intra-observer measurements. The corresponding
values for inter-observer measurements were 12% for both
%ΔLVEDV and %ΔLVESV. Further details for %ΔLVM
and %ΔLVEF are provided in Table 4.
Clinically significant %Δ in LVEDV and LVESV
A total of 146 STEMI patients had matching acute
(mean of 4 ± 2 days) and follow-up CMR scans (median
of 4 (4–5) months). 12/146 (8%) patients had their scans
on a 3 T scanner and the rest were acquired on 1.5 T
scanners. Table 5 summarizes the clinical and CMR
details of these 146 patients.
ROC curve analysis showed that %ΔLVESV was a bet-
ter predictor of LVEF of <50% at follow-up, with an area
under the curve (AUC) of 0.83 (95% CI 0.77 to 0.90),
when compared to an AUC of 0.75 (95% CI 0.67 to 0.83)
for %ΔLVESV, P = 0.03 for ROC curves comparison
(Fig. 3). An 11% increase in %ΔLVEDV had a sensitivity
of 72% and a specificity of 70%, and a 5% increase in
LVESV had both a sensitivity and specificity of 78%.
These cut-off values were lower than the MDC95 for
inter-observer measurements. Therefore, using the cut-
off values for MDC95 for inter-observer measurements
(given that the scans from different studies were by dif-
ferent observers), an increase in LVEDV of 12% had a
sensitivity of 73% and a specificity of 69% and an in-
crease in LVESV of 12% had a sensitivity of 89% and a
specificity of 62% to detect an LVEF of <50%.
Relationship between %ΔLVESV, %ΔLVEDV, %ΔLVEF on
post-STEMI LV remodeling
Figure 4 shows the relationship between %ΔLVESV and
%ΔLVEDV. The dashed lines represent the cut-off
values of +12 and −12% change in LVEDV (vertical
dashed lines) and +12 and −12% change in LVESV
(horizontal dashed lines). Patients were divided into
three groups for %ΔLVEF based on the MDC95 cut-off
of 13% for inter-observer measurements, namely: blue
circles - no change in LVEF at follow-up; green circles -
increase in LVEF at follow-up compared to acute scan;
red circles - decrease in LVEF at follow-up compared to
follow-up. Those with a reduction in LVEF at follow-up
were more likely to have an increase in both LVEDV
and LVESV, and tended to be in the right upper quad-
rant (RUQ) of the graph (adverse LV remodeling
group). Those with an improvement in LVEF were
more likely to have in improvement in LVESV and
LVEDV and tended to be in the middle lower quadrant
(MLQ) and left lower quadrant (LLQ) of the graph (re-
verse LV remodeling group). Some patients had an in-
crease in LVEDV only with or without an improvement
in LVEF, and tended to lie in the right middle quadrant
(RMQ) of the graph (adverse LV remodeling with com-
pensation). Those in the middle quadrant (MQ) of the
Table 1 Characteristics of STEMI patients included for intra-
observer and inter-observer study
Details Number
Number of patients 40
Male (%) 35 (88%)
Age (age) 59 ± 13
Diabetes Mellitus 8 (20%)
Hypertension 14 (35%)
Smoking 12 (30%)
Dyslipidemia 14 (35%)
Chest pain onset to PPCI time (minutes) 267 [122–330]
Infarct artery (%)
LAD 24 (60%)
RCA 14 (35%)
Cx 2 (5%)
Pre-PPCI TIMI flow (%)
0 33 (83%)
1 0 (0%)
2 3 (8%)
3 4 (10%)
Post-PPCI TIMI flow (%)
0 1 (3%)
1 0 (0%)
2 8 (20%)
3 31 (77%)
Acute CMR
LVEDV/ml 172 ± 38
LVESV/ml 90 ± 30
LVM/g 112 ± 35
LVEF/% 49 ± 8
MVO 26 (65%)
MI size/%LV 27.4 ± 14.6
Follow-up CMR
LVEDV/ml 182 ± 49
LVESV/ml 88 ± 38
LVM/g 108 ± 26
LVEF/% 53 ± 10
MI size/%LV 19.5 ± 10.5
PPCI primary percutaneous coronary intervention, LAD left anterior descending
artery, RCA right coronary artery, Cx, circumflex artery, TIMI, thrombolysis in
myocardial infarction, CMR cardiovascular magnetic resonance, LVEDV, left
ventricular end-diastolic volume, LVESV left ventricular end-systole volume,
LVM, left ventricular mass, LVEF, left ventricular ejection fraction, MVO, microvascular
obstruction, MI, myocardial infarct, %LV, percentage of the left ventricle
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graph had no change in LVEDV or LVESV and predom-
inantly no change in LVEF (no remodeling group).
Figure 5 provides a schematic representation for
evaluating LV remodeling post-STEMI from %ΔLVEDV
and %ΔLVESV, using a 2-step approach: firstly the
%ΔLVEDV is evaluated (using a cut-off value of 12%)
and secondly, the %ΔLVESV is assessed as shown in
Fig. 6 (using a cut-off value of 12%). Using this ap-
proach, 4 main patterns of post-STEMI LV remodeling
were observed: Group 1: reverse LV remodeling (with
LVEF predominantly improved, 29% of patients); Group
2: no LV remodeling (with LVEF predominantly un-
changed, 19% of patients); Group 3: adverse LV remod-
eling with compensation (with LVEF predominantly
improved, 14%); and Group 4: adverse LV remodeling
(with LVEF unchanged or worsened, 31%).
Relationship between %ΔLVESV/%ΔLVEDV, MI size and
MVO
The acute MI size was divided into quartiles as follows:
<15%, 15 to 24%, 25 to 33% and ≥33%. Figure 7 shows
the distribution of acute MI size divided by quartiles and
between those without MVO (Fig. 7a) and those with
MVO (Fig. 7b). The incidence of MVO on the acute
CMR scan was 43%, 66, 81 and 78% for those in Group
1 to 4 respectively, P = 0.002. Although those with larger
MI size and MVO were more likely to have adverse LV
remodeling (Group 4 - red box), there were also patients
with small MI sizes and no MVO who went on to de-
velop adverse LV remodeling (green dots within red box
in Fig. 7a) and adverse LV remodeling with compensa-
tion (Group 3 - within yellow box). Likewise, there were
also a notable number of patients with large MI size and
Table 2 Intra-observer and inter-observer variability for LV parameters
Intra- observer Inter-observer
SEM (95% CI) CoV Bias ± limits
of agreement
SEM (95% CI) CoV Bias ± limits
of agreement
T&P included as part of the LV volume
LVEDV
Acute (n = 40) 5.0 (4.1 to 6.4) ml 2.1% 0 ± 7.2 m 5.5 (4.5 to 7.0) ml 2.7% −2.9 ± 9.6 ml
Chronic (n = 40) 5.7 (4.7 to 7.4) ml 2.3% 0.1 ± 8.4 ml 6.3 (5.2 to 8.1) ml 3.3% 0.6 ± 11.8 ml
LVESV
Acute (n = 40) 4.2 (3.5 to 5.4) ml 3.4% −1.4 ± 6.0 ml 4.5 (3.7 to5.7) ml 4.9% −0.6 ± 8.8 ml
Chronic (n = 40) 5.1 (4.2 to 6.5) ml 3.4% −0.1 ± 6.0 ml 5.9 (4.8 to 7.6) ml 5.0% 0 ± 8.8 ml
LVM
Acute (n = 40) 7.4 (6.1 to 9.5) g 3.8% 0.3 ± 8.6 g 7.7 (6.3 to 9.9) g 4.4% −2.2 ± 10.0 g
Chronic (n = 40) 6.6 (5.4 to 8.5) g 4.5% 1.4 ± 9.8 g 7.6 (6.1 to 9.8) g 5.0% −1.8 ± 10.6 g
LVEF
Acute (n = 40) 3.2 (2.7 to 4.2) % 4.1% 0.9 ± 4.0% 2.2 (1.8 to 2.9) % 4.9% −0.4 ± 4.8%
Chronic (n = 40) 1.9 (1.5 to2.4) % 3.2% 0 ± 3.4% 2.7 (2.2 to3.5) % 4.6% 0.2 ± 4.8%
T&P included as part of the LV mass
LVEDV
Acute (n = 40) 5.1 (4.2 to 6.5) ml 2.6% −0.4 ± 8.2 ml 5.3 (4.3 to 6.8) ml 3.1% −2.6 ± 10.0 ml
Chronic (n = 40) 4.1 (3.4 to 5.3) ml 2.5% 0.9 ± 8.2 ml 5.2 (4.3 to 6.7) ml 3.5% −0.4 ± 11.6 ml
LVESV
Acute (n = 40) 4.7 (3.8 to 6.0) ml 3.1% −0.1 ± 4.8 ml 5.5 (4.5 to 7.0) ml 6.1% −2.8 ± 9.8 ml
Chronic (n = 40) 4.4 (3.6 to 5.6) ml 3.5% 1.0 ± 5.2 ml 5.3 (4.3 to 6.8) ml 6.2% −2.2 ± 9.6 ml
LVM
Acute (n = 40) 6.3 (5.2 to 8.1) g 3.2% 0.6 ± 8.2 g 7.4 (6.1 to 9.5) g 4.3% −3.3 ± 11.2 g
Chronic (n = 40) 4.0 (3.3 to 5.2) g 3.4% −0.9 ± 8.0 g 4.2 (3.5 to 5.4) g 5.0% −1.3 ± 11.8 g
LVEF
Acute (n = 40) 1.7 (1.4 to 2.2) % 3.5% −0.2 ± 3.6% 2.4 (2.0 to 3.1) % 6.1% 0.9 ± 6.2%
Chronic (n = 40) 2.0 (1.6 to 2.6)% 3.2% −0.2 ± 3.6% 2.6 (2.2 to 3.4) % 5.1% 1.3 ± 5.8%
SEM standard error of the measurement, CoV coefficient of variation, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systole volume, LVM left
ventricular mass, LVEF left ventricular ejection fraction, T&P trabeculae and papillary muscles
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Fig. 2 Comparison of LV parameters on the acute and follow-up scans with T&P as part of LV volume or as part of LV mass
Table 3 Intra-observer and inter-observer variability for %Δ in LVEDV, LVESV, LVM and LVEF
Intra- observer Inter-observer
SEM (95%CI) Bias ± limits
of agreement
MDC95 SEM (95%CI) Bias ± limits
of agreement
MDC95
T&P included as part of the LV volume
%ΔLVEDV
(n = 40)
3.9 (3.2 to 5.0) % 0.2 ± 6.8% 11% 4.3 (3.6 to 5.6) % 2.2 ± 6.0% 12%
%ΔLVESV
(n = 40)
3.4 (2.8 to 4.4) % 1.5 ± 8.6% 9% 4.0 (3.3 to 5.1) % 0.7 ± 9.8% 11%
%ΔLVM
(n = 40)
3.7 (3.1 to 4.8) % 0.9 ± 8.8% 10% 4.1 (3.4 to 5.3) % 0.2 ± 10.6% 11%
%ΔLVEF
(n = 40)
4.0 (3.2 to 5.1) % −1.5 ± 9.0% 11% 4.2 (3.5 to 5.4) % 1.8 ± 9.8% 12%
T&P included as part of the LV mass
%ΔLVEDV
(n = 40)
3.8 (3.1 to 4.9) % 1.0 ± 8.0% 11% 4.5 (3.7 to 45.7) % 1.5 ± 8.2% 11%
%ΔLVESV
(n = 40)
3.6 (3.0 to 4.6) % 0.8 ± 8.4% 10% 4.5 (3.7 to 5.8) % 1.1 ± 10.0% 12%
%ΔLVM
(n = 40)
4.0 (3.3 to 5.2) % −1.2 ± 9.0% 11% 4.4 (3.6 to 5.6) % 1.3 ± 11.0% 12%
%ΔLVEF
(n = 40)
4.2 (3.5 to 5.4) % 0 ± 9.8% 12% 4.6 (3.8 to 5.9) % 0.3 ± 9.8% 13%
SEM standard error of the measurement, MDC95 minimal detectable change with 95% confidence, %Δ percentage change, LVEDV left ventricular end-diastolic vol-
ume LVESV left ventricular end-systole volume LVM left ventricular mass LVEF left ventricular ejection fraction T&P trabeculae and papillary muscles
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MVO who developed reverse LV remodeling (Group 1 -
black dots within blue box in Fig. 7b).
Discussion
The main findings of this study are as follows: (1) The
MDC95 in %ΔLVEDV and %ΔLVESV of 12% was higher
than the corresponding cut-off values for predicting
LVEF < 50% at follow-up (11% for %ΔLVEDV, and 5%
for %ΔLVESV), providing cut-off values for assessing ad-
verse and reverse LV remodeling following STEMI by
CMR; (2) The MDC95 for %ΔLVM and %ΔLVEF from
the acute to follow-up CMR scan were 12% and 13%, re-
spectively, providing cut-off values for assessing changes
in these LV parameters following STEMI by CMR; (3)
By assessing the combined %ΔLVEDV and %ΔLVESV
between the acute and follow-up CMR, we observed 4
different patterns of LV remodeling following STEMI.
In this study, we measured both intra-observer and
inter-observer variability, and as expected, the MDC95s
for all these LV parameters were greater for inter-
observer than intra-observer measurements. Our ana-
lyses on the whole cohort mainly focused on the inter-
observer rather than the intra-observer measurements
because different operators analyzed the scans from each
study. We found that the inter-observer MDC95s for
%ΔLVEDV and %ΔLVESV between the acute and the
follow-up CMR were 12% each. Using these cut-off
values for defining LV remodeling following STEMI, a
combination of an increase in LVEDV (≥12%) and in
LVESV (≥12%) could be used to identify adverse LV re-
modeling, whereas a decrease in LVESV (≥12%) with or
without a decrease in LVEDV (≥12%) could be used to
identify reverse LV remodeling. However, further studies
are required to investigate the prognostic implications of
these proposed cut-off values for defining adverse and
reverse LV remodeling following STEMI.
As expected, the cut-off value of 12% or more for
%ΔLVEDV to define adverse LV remodeling obtained in
our cohort is significantly lower than that defined by
echocardiography (20% or more for %ΔLVEDV). This is
due to the better spatial resolution of CMR and superior
Table 4 Cut-off values for LVEDV and LVESV in STEMI patients
in our cohort (irrespective of whether T&P considered as part of
LV volume or LV mass)
MDC95
Intra-observer Inter-observer
%ΔLVEDV 11% 12%
%ΔLVESV 10% 12%
%ΔLVM 11% 12%
%ΔLVEF 12% 13%
MDC95 minimal detectable change with 95% confidence, %Δ percentage
change, LVEDV left ventricular end-diastolic volume LVESV left ventricular
end-systolic volume
Table 5 Total number of patients with paired acute and follow-
up scan from 4 studies
Details Number
Number of patients 146
Ludman 2011 [16] 29 (20%)
Crimi 2013 [17] 65 (45%)
Bulluck 2016 [18] 12 (8%)
Bulluck 2016 [19] 40 (27%)
Male 129 (88%)
Age (years) 59 ± 12
Diabetes Mellitus 15 (10%)
Hypertension 67 (46%)
Smoking 64 (44%%)
Dyslipidemia 47 (32%)
Chest pain onset to PPCI time (minutes) 184 [135–282]
Infarct artery (%)
LAD 109 (75%)
RCA 29 (20%)
Cx 8 (6%)
TIMI flow pre-PPCI
0 129 (89%)
1 7 (5%)
2 4 (3%)
3 4 (3%)
TIMI flow post-PPCI
0 2 (1%)
1 2 (1%)
2 23 (16%)
3 117 (82%)
Timing of acute CMR 4 ± 2 days
Timing of follow-up CMR 4 (4–5) months
CMR findings- acute
LVEDV 156 (132–183) ml
LVESV 80 (64–103) ml
LVM 121 (104–145) g
LVEF 47 ± 9%
MI size 24.6 ± 12.1%LV
MVO 96 (66%)
CMR findings- follow-up
LVEDV 165 (141–201) ml
LVESV 82 (60–109) ml
LVM 106 (90–132) g
LVEF 50 ± 11%
MI size 17.8 ± 10.1%LV
PPCI primary percutaneous coronary intervention, LAD left anterior
descending artery, RCA right coronary artery, Cx circumflex artery, TIMI
thrombolysis in myocardial infarction, CMR cardiovascular magnetic
resonance, LVEDV left ventricular end-diastolic volume LVESV left ventricular
end-systole volume, LVM left ventricular mass, LVEF left ventricular ejection
fraction, MI myocardial infarct, MVO, microvascular obstruction
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intra-observer and inter-observer variability [6]. On the
other hand, the cut-off value for defining reverse LV re-
modeling as ≥12% for %ΔLVESV from our study is
higher than the 10% cut-off value currently proposed by
echocardiography [10]. The echocardiography-based
method was derived using ROC curve for the optimal
cut-off for decrease in ESV to predict mortality in pa-
tients undergoing cardiac resynchronization therapy and
they did not perform inter-observer and intra-observer
variability for change in LVESV. It is highly likely that
the inter-observer and intra-observer for %ΔLVESV by
echocardiography in STEMI patients would be higher
than the CMR cut-off value we obtained.
Currently there is no consensus on whether T&P should
be included as part of the LV volume or as part of LV mass
during LVEF and LVM assessment by CMR [5]. We there-
fore provided MDC95 for %ΔLVEDV, %ΔLVESV, %ΔLVM,
and %ΔLVEF using both approaches. It is already known
that the T&P can significantly affect LV volumes, LV mass,
and LVEF [23, 24]. We found that LVEDV and LVESV
were higher, and LVM and LVEF were lower when T&P
were included as part of the LV volume, and this is con-
sistent with previous reports [23–25]. As their inclusion
Fig. 3 ROC curve comparison for %ΔLVEDV and %ΔLVESV to detect
LVEF < 50% at follow-up
Fig. 4 Relationship between %ΔLVEDV, %ΔLVESV and %ΔLVEF. The vertical dashed lines represent the cut-off values of +12 and −12% change in
LVEDV and the horizontal dashed lines represent +12 and −12% %ΔLVESV. Patients were divided into 3 groups for %ΔLVEF based on the MDC95
cut-off of 13%, namely: blue circles - no change in LVEF at follow-up; green circles - increase in LVEF at follow-up compared to acute scan; red
circles - decrease in LVEF at follow-up compared to acute scan. Those with a reduction in LVEF at follow-up were more likely to have an increase in
both LVEDV and LVESV, and tended to be in the right upper quadrant (RUQ) of the graph. Those with an improvement in LVEF were more likely to
have a reduction in LVESV and LVEDV and tended to be in the middle lower quadrant (MLQ) and left lower quadrant (LLQ) of the graph. Some
patients had an increase in LVEDV only with or without an improvement in LVEF, and tended to lie in the right middle quadrant (RMQ) of the
graph. Those in the middle quadrant (MQ) of the graph had no change in LVEDV or LVESV and predominantly no change in LVEF
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Fig. 5 Schematic representation of the different groups of remodeling. Based on the %ΔLVEDV and %ΔLVESV between the follow-up and acute
CMR, patients would predominantly fall into these 4 main patterns of LV remodeling groups
Fig. 6 the evaluation of LV remodeling using a 2-step approach. Using a 2-step approach and a combination of %ΔLVEDV and %ΔLVESV, patients
can be easily classified into these 4 groups
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as part of the LV mass is not always practical depending
on the software, both methods are currently considered
acceptable [5]. Although the LV parameters differed de-
pending on how the T&P were dealt with, there were no
difference in the CoVs both for inter or intra-observer
measurements for LVEDV, LVESV, LVM and LVEF when
T&P were included as part of the LV volume or LV mass.
However, the MDC95 for intra-observer and inter-
observer measurements for %Δ in LV parameters varied
by 1–2% depending on whether the T&P were included as
part of the LV volume or LV mass. We therefore provided
the highest MDC95 for each LV parameter in Table 4,
irrespective how the T&P were dealt with.
In the absence of clinical outcomes, LVEF <50% in
patients with scars have previously been shown to be as-
sociated with poor clinical outcomes [15]. Using this
cut-off for LVEF at follow-up as a surrogate marker, we
obtained cut-off values for %ΔLVEDV and %ΔLVESV of
11 and 5%, respectively. These figures were lower than
that defined by our MDC95 cut-off values of 12% for
both %ΔLVEDV and %ΔLVESV. The MDC and the clin-
ically significant change are independent of each other
as they are derived in different ways and in our case, the
former turned out to be larger than the latter. Therefore
we chose the cut-off values of MDC95 to define LV
remodeling in the whole cohort.
Using the combination of %ΔLVEDV and %ΔLVESV
from the acute to the follow-up CMR, we observed 4
different patterns of post-STEMI remodeling (Figs. 5
and 6) The actual impact of these 4 different patterns of
post-STEMI LV modeling on clinical outcome will need
to be determined in future studies. Conventionally,
adverse LV remodeling post-STEMI has been defined by
%ΔLVEDV. Our data, suggests that assessing both
%ΔLVEDV and %ΔLVESV, may provide further insights
into different patterns of LV remodeling following
STEMI, thereby allowing one to customize heart failure
therapy to prevent adverse LV remodeling or promote
reverse LV remodeling. Orn et al. [26] described three
patterns of LV remodeling based on presence and per-
sistence of MVO by CMR within the first week of an
acute STEMI in a serial CMR study of 42 patients. Most
LV remodeling occurred by 2 months and continued to
at least 1 year. Those with no MVO had a normal
a b
Fig. 7 Relation between %ΔLVEDV/%ΔLVEV and different quartiles of acute MI size in (a) patients without MVO and (b) patients with MVO.
Some patients with small MI and no MVO (green dots in 6a) developed adverse LV remodeling (falling within the red box or yellow box in 6a) with
others with large MI and MVO (black dots in 6b) developed reverse LV remodeling or no remodeling (falling within the green or blue box in 6b)
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pattern of wound healing; those with MVO on day 2
only, they dilated their ventricle but adapted function-
ally; and the last group were those with persistent MVO
at 1 week and they dilated their ventricle without the
ability to adapt functionally. These three groups bear
some resemblance to the groups of LV remodeling we
identified but we did not have serial CMR data on MVO
for comparison. Other factors that determine the pattern
of LV remodeling post-STEMI also require further
study.
Westman et al. [1] recently showed that there was an
imperfect link between MI size and adverse LV remodeling
(defined as >10 ml/m2 increase in indexed LVEDV).
Several studies have also shown that MVO was a strong
predictor of adverse LV remodeling [27]. Using the def-
inition in our study for adverse LV remodeling, we also
showed that there was an imperfect link between acute
MI size and adverse LV remodeling as well between
MVO and adverse LV remodeling. Some patients with
large MI size and MVO developed reverse LV remodeling
and some patients with small MI size and no MVO de-
veloped adverse LV remodeling. As eluded by Westman
et al. [1], the development of adverse LV remodeling is
complex and multi-factorial, and more work is war-
ranted in this field.
We found the MDC95 in %ΔLVM between acute and
follow-up scans to be ≥12%, suggesting that this would
be the minimal change in LVM that is unlikely due to
inter-observer measurement errors. However, the inter-
pretation of changes in LVM following STEMI is com-
plicated by the fact that on the acute scan, the presence
of myocardial edema also contributes to the changes in
LVM acutely and therefore we did not investigate
%ΔLVM in post-STEMI LV remodeling. However, it
would be interesting to determine the MDC95 for asses-
sing %ΔLVM in patients with LV hypertrophy related to
hypertension or aortic valve disease, in order to provide
cut-off values which can be used in studies assessing the
regression of LV hypertrophy.
Finally, we found the MDC95 for % ΔLVEF to be
≥13% in STEMI patients when using CMR. This finding
suggests that only a relative change in LVEF of 13% or
more can be reliably detected by CMR as being beyond
inter-observer measurement errors. This is equivalent to
an absolute change of 6.5% in a patient with an acute
LVEF of 50%. This needs to be taken into consideration
when planning future studies designed to investigate
new treatments for improving LVEF following STEMI.
Limitations
Inter-observer and intra-observer measurements were
performed in only 40 patients (80 scans) but this is sig-
nificantly larger than the number of patients used in a
previous study (n = 10) providing the minimal detectable
change in LVEF by echocardiography in patients under-
going chemotherapy (10 patients with echocardiography
at 2 time-points) [22]. We only used one analysis tool and
LV parameters were quantified using the semi-automated
method. We did not have matching echocardiography
data for comparison. We did not have complete data on
the presence of multi-vessel disease or clinical outcomes
and our sample size was relatively small. Therefore, we
used an LVEF of <50% at follow-up as a surrogate. [15]
There was heterogeneity in the performance of CMR for
acute MI size and MVO (scanner strength, dosage and
type of contrast, timing of LGE for MVO and MI,
quantification technique used – Additional file 1: On-
line appendix Table 1) and our findings need to be con-
firmed by future studies.
Conclusions
The MDCs for %ΔLVEDV and %ΔLVESV between the
acute and follow-up CMR scans of 12% each may be
used to help define adverse and reverse LV remodeling
post-STEMI. Combining %ΔLVEDV and %ΔLVESV fol-
lowing STEMI may provide additional insights into the
different pattern of LV remodeling, but their prognostic
impact needs to be assessed in future studies. Finally,
the MDC for %ΔLVEF of 13% relative to baseline pro-
vides the minimal effect size that needs to be taken into
consideration when investigating treatments aimed at
improving LVEF following acute STEMI.
Additional file
Additional file 1: Online appendix Table 1: CMR acquisition details of
the 4 studies included. (DOCX 26 kb)
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